Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01563445 · ClinicalTrials.gov registry record · Phase 2

Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII for Preventing Early Hematoma Growth in Acute Intracerebral Haemorrhage

A Phase 2 study, sponsored by Novo Nordisk A/S.

Completed
Registry status
Phase 2
Development phase
40
Enrollment target

NCT01563445: Completed Phase 2 study, sponsored by Novo Nordisk A/S.

NCT01563445 is a Phase 2 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 40 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01563445, a Phase 2 study, has completed, sponsored by Novo Nordisk A/S.

COMPLETED
Registry status
Phase 2
Development phase
40 participants
Enrollment target

Study Summary

This trial is conducted in the United States of America (USA). The aim of this trial is to evaluate the safety and preliminary efficacy of activated recombinant human factor VII (NovoSeven®) for preventing early hematoma growth in acute Intracerebral Hemorrhage (ICH).

Interventions

  • DRUG placebo
  • DRUG activated recombinant human factor VII

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2001-11
Est. Completion 2003-03
Phase Phase 2
Novo Nordisk A/S

431 total trials

What the finished NCT01563445 record still lists

NCT01563445 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (70% lower).

The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.

NCT01563445 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01563445 about?

NCT01563445 is a clinical study titled "Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII for Preventing Early Hematoma Growth in Acute Intracerebral Haemorrhage". This trial is conducted in the United States of America (USA). The aim of this trial is to evaluate the safety and preliminary efficacy of activated recombinant human factor VII (NovoSeven®) for preventing early hematoma growth in acute Intracerebral Hemorrhage (ICH).

What is the current status of trial NCT01563445?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2001-11. Estimated completion is 2003-03.

What interventions are being tested in trial NCT01563445?

The interventions under investigation include: placebo (DRUG), activated recombinant human factor VII (DRUG).

Who is sponsoring clinical trial NCT01563445?

This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01563445's enrollment target sits among peer trials

40 1362nd of 2000 higher than 542 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01563445, the US trial registry maintained by the National Library of Medicine. NCT01563445 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.